Activating HER2 mutations are rare in NSCLC, with a prevalence of 2–4%, but they are successfully targeted with trastuzumab or trastuzumab deruxtecan (T-DXd) [183]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.